Put companies on watchlist
Viromed Medical AG
ISIN: DE000A3MQR65
WKN: A3MQR6
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Viromed Medical AG · ISIN: DE000A3MQR65 · EQS - adhoc news (8 News)
Country: Germany · Primary market: Germany · EQS NID: 1940807
05 July 2024 05:30PM

Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect


EQS-Ad-hoc: Viromed Medical AG / Key word(s): Miscellaneous
Viromed Medical AG: Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect

05-Jul-2024 / 17:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Viromed Medical AG: Viromed Medical GmbH and terraplasma medical GmbH terminate their cooperation with immediate effect

Pinneberg, 5 July 2024 –
Viromed Medical GmbH, a wholly owned subsidiary of Viromed Medical AG, and terraplasma medical GmbH have today terminated their business relation with immediate effect.

As part of the previous cooperation, Viromed Medical GmbH held the exclusive distribution rights for a cold plasma device developed by terraplasma medical GmbH in the German-speaking region (Germany, Austria, Switzerland), with which Viromed Medical GmbH generated slightly less than half of its annual revenue in the 2023 financial year.

Already in the past, various manufacturers of comparable devices had expressed interest in cooperating with Viromed Medical GmbH. However, given the exclusivity agreement with terraplasma medical GmbH, Viromed Medical GmbH was unable to take advantage of these opportunities. This restriction now no longer applies, so that Viromed Medical AG sees the possibility of expanding its sales potential in future by selling its own cold plasma devices worldwide.

Viromed Medical AG plans to be present on the market with its own cold plasma product series at the beginning of the fourth quarter of 2024. As a first step, Viromed Medical AG is planning to enter the European market.

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Strasse 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de



End of Inside Information

05-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg
EQS News ID: 1940807

 
End of Announcement EQS News Service

1940807  05-Jul-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1940807&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Viromed Medical AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.